Evidence map›Paper›PMID 32751183›Full record

ReviewCancers2020

The HECT E3 Ligase E6AP/UBE3A as a Therapeutic Target in Cancer and Neurological Disorders.

Asia Owais, Rama K Mishra, Hiroaki Kiyokawa

Open access · goldAbstract readReview
In one paragraph

Review in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 39 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Ubiquitin E3 Ligases and p53 in Doxorubicin-Induced Cardiotoxicity.International journal of molecular sciences · 2025
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Unraveling the Roles of UBE3A in Neurodevelopment and Neurodegeneration.International journal of molecular sciences · 2025
    Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Asia OwaisDepartment of Pharmacology, Northwestern University, Chicago, IL 60611, USA.
Rama K MishraDepartment of Biochemistry and Molecular Genetics, Northwestern University, Chicago, IL 60611, USA.
Hiroaki KiyokawaDepartment of Pharmacology, Northwestern University, Chicago, IL 60611, USA.ORCID 0000-0002-7942-6455
Northwestern University · US

Funding

Orthogonal Ubiquitin Transfer to Profile E3 Substrate Specificity.R01GM104498 · NIGMS · UNIVERSITY OF CHICAGO · PI KIYOKAWA, HIROAKI, YIN, JUN · 2013 to 2021
$3.2M
chicago biomedical consortium CatalystNIGMS NIH HHS R01-GM104498
6 · The paper itself

Abstract

The HECT (Homologous to the E6-AP Carboxyl Terminus)-family protein E6AP (E6-associated protein), encoded by the

Indexed as

Angelman syndromeautismchromosome 15qE3 ligaseimprintingoncoproteinssmall moleculestumor suppressorsubiquitinviral oncogenesis

Identifiers

PMID32751183
PMCPMC7464832
OpenAlexW3045966719

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.